amyotrophic lateral sclerosis
MHRA approves Pharma Mar’s lurbinectedin for extensive-stage small cell lung cancer
The treatment is for adults in combination with atezolizumab
Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes
The UK is the first country in Europe to authorise the oral medication
Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved
The real-world findings support the long-term benefits of continuous treatment
Biogen to acquire RayThera in $1bn deal
The acquisition will expand the company’s immunology pipeline
Biogen’s salanersen gets FDA Breakthrough Therapy Designation for SMA
In the study, there were improvements in motor function as well as a slowing of neurodegeneration
Biogen agrees $850m felzartamab rights deal with TJ Biopharma
The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases
MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment
SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
UK clinical trial regs are changing — here’s what’s happening
Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.
Biogen to acquire Apellis in $5.6bn deal
The deal will enhance Biogen’s growth portfolio in immunology and rare disease
Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term
The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark